{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:33Z","timestamp":1790797053790,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Due to the low incidence of male microprolactinoma, there is a paucity of data in the literature regarding its management. Our aim was to investigate the long-term outcomes of cabergoline treatment in men with microprolactinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this single-center retrospective cohort study, we reviewed patient\u2019s records at prolactinoma diagnosis, following cabergoline discontinuation (if occurred), and at the last clinic visit. We collected all available clinical data, laboratory tests, and pituitary magnetic resonance imaging. We report response rates, gonadal axis recovery, and outcomes following cabergoline discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study cohort included 47 men with microprolactinoma [age at diagnosis 45.6\u2009\u00b1\u200917.6 years; median prolactin 70.0\u2009ng\/ml (IQR 51.0\u2013103.4); low testosterone, 34 men (72.3%); adenoma diameter 5.6\u2009\u00b1\u20092.0\u2009mm; median follow-up 7.1 years (IQR 3.5\u201310.4)]. Forty-two patients (89.4%) achieved normal prolactin levels within a median treatment time of 4.0 months (IQR 3.0\u20135.5) and had normal testosterone at last clinic visit. Five men (10.6%) did not achieve prolactin normalization, of whom 3 men remained hypogonadal. Mild side effects occurred in 4.3% of patients and disappeared with dose reduction. Thirteen men that achieved normal prolactin attempted drug discontinuation, but only 5 remained with normoprolactinemia. Men who maintained normal prolactin levels were treated longer with cabergoline [median treatment of 10 years (IQR 4.6\u201310.3) vs 2.0 years (IQR 1.5\u20133.2); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Ninety percent of men harboring microprolactinoma achieved normoprolactinemia and subsequent testosterone normalization with cabergoline treatment. Men that discontinued cabergoline after prolonged prolactin suppression (&gt;5 years) achieved sustained remission. These findings assist informed decision-making, between medical and surgical treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-025-04215-w","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:49:16Z","timestamp":1744159756000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-6321","authenticated-orcid":false,"given":"Yaron","family":"Rudman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-3906","authenticated-orcid":false,"given":"Genady","family":"Drozdinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5643-445X","authenticated-orcid":false,"given":"Efrat","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-1360","authenticated-orcid":false,"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-8025","authenticated-orcid":false,"given":"Hiba","family":"Masri-Iraqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2033-7300","authenticated-orcid":false,"given":"Gloria","family":"Tsvetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-344X","authenticated-orcid":false,"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3894","authenticated-orcid":false,"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"3","key":"4215_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"A Fernandez, N Karavitaki, JA Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. endocrinol. (Oxf.). 72(3), 377\u2013382 (2010). https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x.","journal-title":"Clin. endocrinol. (Oxf.)."},{"issue":"3","key":"4215_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"T Mindermann, CB Wilson, Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxf.). 41(3), 359\u2013364 (1994). https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02557.x.","journal-title":"Clin. Endocrinol. (Oxf.)."},{"issue":"2","key":"4215_CR3","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"P Chanson, D Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33(2), 101290 (2019). https:\/\/doi.org\/10.1016\/j.beem.2019.101290.","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"9","key":"4215_CR4","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1210\/jcem.85.9.6798","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"JJ Pinzone, L Katznelson, DC Danila, DK Pauler, CS Miller, A Klibanski, Primary medical therapy of micro- and macroprolactinomas in men. J. clin. Endocrinol. Metab. 85(9), 3053\u20133057 (2000). https:\/\/doi.org\/10.1210\/jcem.85.9.6798.","journal-title":"J. clin. Endocrinol. Metab."},{"issue":"4","key":"4215_CR5","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"A Colao, G Vitale, P Cappabianca, F Briganti, A Ciccarelli, MDe Rosa, S Zarrilli, G Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. clin. Endocrinol. Metab. 89(4), 1704\u20131711 (2004). https:\/\/doi.org\/10.1210\/jc.2003-030979.","journal-title":"J. clin. Endocrinol. Metab."},{"issue":"1","key":"4215_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s0015-0282(16)55139-5","volume":"58","author":"AV Sluijmer","year":"1992","unstructured":"AV Sluijmer, RE Lapp\u00f6hn, Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil. Steril. 58(1), 72\u201377 (1992). https:\/\/doi.org\/10.1016\/s0015-0282(16)55139-5.","journal-title":"Fertil. Steril."},{"issue":"7","key":"4215_CR7","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"J Verhelst, R Abs, D Maiter, Avan den Bruel, M Vandeweghe, B Velkeniers, J Mockel, G Lamberigts, P Petrossians, P Coremans, C Mahler, A Stevenaert, J Verlooy, C Raftopoulos, A Beckers, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. clin. Endocrinol. Metab. 84(7), 2518\u20132522 (1999). https:\/\/doi.org\/10.1210\/jcem.84.7.5810.","journal-title":"J. clin. Endocrinol. Metab."},{"key":"4215_CR8","doi-asserted-by":"publisher","unstructured":"E Soto-Pedre, PJ Newey, JS Bevan, N Greig, GP Leese, The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS. Clin. Endocrinol. (Oxf.). 86(1), 60\u201367 (2017). https:\/\/doi.org\/10.1111\/cen.13156.","DOI":"10.1111\/cen.13156"},{"issue":"8","key":"4215_CR9","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"M Kars, PC Souverein, RM Herings, JA Romijn, JP Vandenbroucke, Ade Boer, OM Dekkers, Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 94(8), 2729\u20132734 (2009). https:\/\/doi.org\/10.1210\/jc.2009-0177.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4215_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"S Ezzat, SL Asa, WT Couldwell, CE Barr, WE Dodge, ML Vance, IE McCutcheon, The prevalence of pituitary adenomas: a systematic review. Cancer 101(3), 613\u2013619 (2004). https:\/\/doi.org\/10.1002\/cncr.20412.","journal-title":"Cancer"},{"issue":"13","key":"4215_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"A Klibanski, Clinical practice. Prolactinomas. N. Engl. J. Med. 362(13), 1219\u20131226 (2010). https:\/\/doi.org\/10.1056\/NEJMcp0912025.","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"4215_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","volume":"23","author":"V Bonert","year":"2020","unstructured":"V Bonert, Do nothing but observe microprolactinomas: when and how to replace sex hormones?. Pituitary 23(3), 307\u2013313 (2020). https:\/\/doi.org\/10.1007\/s11102-020-01039-x.","journal-title":"Pituitary"},{"key":"4215_CR13","doi-asserted-by":"publisher","unstructured":"S Melmed, FF Casanueva, AR Hoffman, DL Kleinberg, VM Montori, JA Schlechte, JA Wass, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273\u2013288 (2011). https:\/\/doi.org\/10.1210\/jc.2010-1692. Endocrine Society.","DOI":"10.1210\/jc.2010-1692"},{"issue":"12","key":"4215_CR14","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","volume":"44","author":"L Andereggen","year":"2021","unstructured":"L Andereggen, J Frey, RH Andres, MM Luedi, M El-Koussy, HR Widmer, J Beck, L Mariani, RW Seiler, E Christ, First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J. Endocrinol. Invest. 44(12), 2621\u20132633 (2021). https:\/\/doi.org\/10.1007\/s40618-021-01569-6.","journal-title":"J. Endocrinol. Invest."},{"issue":"12","key":"4215_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"S Petersenn, M Fleseriu, FF Casanueva, A Giustina, N Biermasz, BMK Biller, M Bronstein, P Chanson, H Fukuoka, M Gadelha, Y Greenman, M Gurnell, KKY Ho, J Honegger, AG Ioachimescu, UB Kaiser, N Karavitaki, L Katznelson, M Lodish, D Maiter, S Melmed, Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 19(12), 722\u2013740 (2023). https:\/\/doi.org\/10.1038\/s41574-023-00886-5.","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"4215_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","volume":"77","author":"P Iglesias","year":"2012","unstructured":"P Iglesias, C Bernal, C Villabona, JC Castro, F Arrieta, JJ D\u00edez, Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin. endocrinol. (Oxf.). 77(2), 281\u2013287 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04351.x.","journal-title":"Clin. endocrinol. (Oxf.)."},{"key":"4215_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"L Andereggen, J Frey, RH Andres, M El-Koussy, J Beck, RW Seiler, E Christ, Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World. Neurosurg. 97, 595\u2013602 (2017). https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059.","journal-title":"World. Neurosurg."},{"issue":"21","key":"4215_CR18","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"A Colao, ADi Sarno, P Cappabianca, CDi Somma, R Pivonello, G Lombardi, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349(21), 2023\u20132033 (2003). https:\/\/doi.org\/10.1056\/NEJMoa022657.","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"4215_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"OM Dekkers, J Lagro, P Burman, JO J\u00f8rgensen, JA Romijn, AM Pereira, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. clin. Endocrinol. Metab. 95(1), 43\u201351 (2010). https:\/\/doi.org\/10.1210\/jc.2009-1238.","journal-title":"J. clin. Endocrinol. Metab."},{"issue":"1","key":"4215_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11102-010-0251-6","volume":"14","author":"I Shimon","year":"2011","unstructured":"I Shimon, C Benbassat, G Tzvetov, S Grozinsky-Glasberg, Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14(1), 11\u201315 (2011). https:\/\/doi.org\/10.1007\/s11102-010-0251-6.","journal-title":"Pituitary"},{"issue":"8","key":"4215_CR21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1373\/clinchem.2015.240531","volume":"61","author":"K Adeli","year":"2015","unstructured":"K Adeli, JE Raizman, Y Chen, V Higgins, M Nieuwesteeg, M Abdelhaleem, SL Wong, D Blais, Complex biological profile of hematologic markers across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin. Chem. 61(8), 1075\u20131086 (2015). https:\/\/doi.org\/10.1373\/clinchem.2015.240531.","journal-title":"Clin. Chem."},{"issue":"6","key":"4215_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","volume":"37","author":"J Webster","year":"1992","unstructured":"J Webster, G Piscitelli, A Polli, A D\u2019Alberton, L Falsetti, C Ferrari, P Fioretti, G Giordano, M L\u2019Hermite, E Ciccarelli, Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin. endocrinol. (Oxf.). 37(6), 534\u2013541 (1992). https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb01485.x.","journal-title":"Clin. endocrinol. (Oxf.)."},{"issue":"3","key":"4215_CR23","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"M Tampourlou, R Trifanescu, A Paluzzi, SK Ahmed, N Karavitaki, Therapy of endocrine disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur. J. Endocrinol. 175(3), R89\u2013R96 (2016). https:\/\/doi.org\/10.1530\/EJE-16-0087.","journal-title":"Eur. J. Endocrinol."},{"key":"4215_CR24","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1016\/j.wneu.2022.12.003","volume":"170","author":"A Uzuner","year":"2023","unstructured":"A Uzuner, E Yilmaz, M Caklili, A Selek, F Aydemir, B Cabuk, I Anik, S Ceylan, Endoscopic transnasal approach for microprolactinomas with experience of 105 cases in a single center: paradigmal shift for conventional medical therapy. World. Neurosurg. 170, e858\u2013e867 (2023). https:\/\/doi.org\/10.1016\/j.wneu.2022.12.003.","journal-title":"World. Neurosurg."},{"issue":"4","key":"4215_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cen.14541","volume":"95","author":"Y Rudman","year":"2021","unstructured":"Y Rudman, H Duskin-Bitan, Y Manisterski, B Pertzov, A Akirov, H Masri-Iraqi, I Shimon, Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?. Clin. endocrinol. (Oxf.). 95(4), 606\u2013617 (2021). https:\/\/doi.org\/10.1111\/cen.14541.","journal-title":"Clin. endocrinol. (Oxf.)."},{"issue":"3","key":"4215_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s12020-021-02624-1","volume":"72","author":"I Shimon","year":"2021","unstructured":"I Shimon, Y Rudman, Y Manisterski, A Gorshtein, H Masri, H Duskin-Bitan, True hyperprolactinemia in men without visible pituitary adenoma. Endocrine 72(3), 809\u2013813 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02624-1.","journal-title":"Endocrine"},{"issue":"6","key":"4215_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Y Rudman, H Duskin-Bitan, H Masri-Iraqi, A Akirov, I Shimon, Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6), 882\u2013890 (2022). https:\/\/doi.org\/10.1007\/s11102-022-01259-3.","journal-title":"Pituitary"},{"issue":"5","key":"4215_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","volume":"27","author":"SM Constantinescu","year":"2024","unstructured":"SM Constantinescu, D Maiter, O Alexopoulou, Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists. Pituitary 27(5), 625\u2013634 (2024). https:\/\/doi.org\/10.1007\/s11102-024-01445-5.","journal-title":"Pituitary"},{"issue":"7","key":"4215_CR29","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/andr.13428","volume":"11","author":"Y Rudman","year":"2023","unstructured":"Y Rudman, H Duskin-Bitan, I Richter, G Tsvetov, H Masri-Iraqi, A Akirov, I Shimon, Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men. Andrology 11(7), 1398\u20131407 (2023). https:\/\/doi.org\/10.1111\/andr.13428.","journal-title":"Andrology"},{"issue":"4","key":"4215_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"E Knosp, E Steiner, K Kitz, C Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610\u2013618 (1993). https:\/\/doi.org\/10.1227\/00006123-199310000-00008.","journal-title":"Neurosurgery"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04215-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:49:10Z","timestamp":1751611750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04215-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04215-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}